Keros Therapeutics, Inc.
ACTIVIN RECEPTOR TYPE IIA VARIANTS AND METHODS OF USE THEREOF

Last updated:

Abstract:

The invention features polypeptides that include an extracellular ActRIIA variant. In some embodiments, a polypeptide of the invention includes an extracellular ActRIIA variant fused to an Fc domain monomer or moiety. The invention also features pharmaceutical compositions and methods of using the polypeptides to treat diseases and conditions involving low red blood cell levels, e.g., anemia or blood loss; fibrosis; or pulmonary hypertension.

Status:
Application
Type:

Utility

Filling date:

6 Nov 2020

Issue date:

25 Feb 2021